WeForNews | Latest News, Breaking News, News Updates Antibody testing suggests 2.7mn in New York could be COVID-19 infected | WeForNews | Latest News, Blogs
Connect with us

Health

Antibody testing suggests 2.7mn in New York could be COVID-19 infected

New York state egistered over 19,500 COVID-19 fatalities by Thursday, with over 15,000 in New York City, according the the Johns Hopkins’ tally.

Published

on

COVID-19 antibody testing

New York, April 24 : New York, the epicentre of the coronavirus pandemic in the US, has seen 13.9 per cent positive results in the state’s antibody tests, which means around 2.7 million people could be infected with the COVID-19, Governor Andrew Cuomo said.

Launched by the state’s health department earlier this week, the testing collected samples of 3,000 supermarket shoppers from 40 locations in 19 counties in the state, Xinhua news agency quoted Cuomo as saying on Thursday.

The preliminary results suggest the real number of total infected in the state’s 19.45 million people could be ten times higher than the official data, which stood at 263,754 on Thursday, according to the Johns Hopkins University.

People who have tested positive in the antibody testing are those who were infected with coronavirus and then recovered.

The testing offers a snapshot of the infection rate statewide and is considered a major step in determining when and how to restart the economy.

New York City has shown a 21.2 per cent positivity rate in the testing, higher than anywhere else in the state.

Long Island had a 16.7 per cent positivity rate, while 11.7 per cent in Westchester county and Rockland county tested positive. The rest of the state registered 3.6 per cent.

The racial breakdown shows the positivity rates of Asians, Blacks, Latinos and Whites in the state are 11.7, 22.1, 22.5 and 9.1 per cent, respectively.

Meanwhile, 12 per cent of females tested positive and 15.9 per cent of males tested positive.

The results also indicated that the real mortality rate could be around 0.5 per cent in the state, much lower than the 7 per cent calculated from official numbers.

However, it’s not sure how telling the results are.

“These are people who were out and about shopping. They were not people who were in their homes, they were not people who were isolated, they were not people who were quarantined,” said Cuomo.

Oxiris Barbot, New York City’s Commissioner of Health, said on Thursday that the 138,000- plus confirmed COVID-19 cases in the city is just “the tip of the iceberg” as diagnostic testing was very limited at the beginning of the outbreak.

“It wouldn’t surprise me if at this point in time we have probably close to a million New Yorkers who have been exposed to COVID-19,” she said at the mayor’s daily briefing.

New York state egistered over 19,500 COVID-19 fatalities by Thursday, with over 15,000 in New York City, according the the Johns Hopkins’ tally.

Cities

Delhi reports 51 cases of minor adverse events post vaccination

As many as 1,91,181 people were vaccinated on day one of India’s first phase of the coronavirus vaccination drive.

Published

on

By

Covid 19 Vaccine

Hours after the Health Ministry announced on January 16 that India has reported no case of post-vaccination hospitalisation yet, 51 persons complained of minor adverse events in Delhi. Another person developed severe adverse event following immunization and had to be referred to the AEFI centre.

Out of a total of 4,319 healthcare and frontline workers who were vaccinated on Jnauary 16 in the National Capital, two healthcare workers at NDMC’s Charak Palika Hospital reported mild adverse event post-vaccination including mild tightness in the chest. They were kept under observation by AEFI team and discharged 30 minutes later after they felt at ease. The two other cases were reported from Northern Railway Central Hospital, of which one was referred to the AEFI centre, the Delhi government has informed.

As many as 1,91,181 people were vaccinated on day one of India’s first phase of the coronavirus vaccination drive.

Beneficiaries from 11 states and union territories across India received Covishield or Covaxin shots on the first day of the vaccination drive, namely, Assam, Bihar, Delhi, Haryana, Karnataka, Maharashtra, Odisha, Rajasthan, Tamil Nadu, Telangana, and Uttar Pradesh.

Follow our coverage of the coronavirus crisis here

Continue Reading

Health

Bharat Biotech to pay compensation if Covaxin causes side-effects

The vaccine maker said in phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID- 19

Published

on

By

COVAXIN Corona Covid vaccine

Hyderabad, January 16: Bharat Biotech, which has received a government purchase order for supply of 55 lakh doses of Covaxin, a COVID-19 vaccine, said the company would pay compensation to recipients in case of any serious adverse effects experienced after receiving the antidote.

In the consent form to be signed by the vaccine recipients, Bharat Biotech said: “In case of any adverse events or serious adverse events, you will be provided medically recognised standard of care in the government designated and authorised centres/hospitals.”

“The compensation for serious adverse event will be paid by sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine,” the consent form said.

In phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID- 19. However, the clinical efficacy of the vaccine was yet to be established and it was still being studied in phase 3 clinical trials, the vaccine maker said.

“Hence it is important to appreciate that receiving the vaccine does not mean that other precautions related to COVID-19 need not be followed,” the consent form said.

According to an industry expert, the company is liable to pay compensation to people in case of serious side effects as the vaccine is being administered while in the clinical trial mode.

The central licensing authority has granted permission for the sale or distribution of Covaxin for restricted use in emergency situations in public interest as an abundant caution, in clinical trial mode.

Meanwhile, Suchitra Ella, joint managing director, Bharat Biotech International Limited, on her Twitter account said: “Covaxin & Bharat Biotech is truly humbled & honoured to be of service to the nation & the fraternity of all first responders of covid who have served public health.” — PTI

Continue Reading

Cities

AIIMS security guard reports allergy post COVID vaccination, in hospital care

Delhi has reported 52 adverse events following events of which one is serious and could involve the guard hospitalised today.

Published

on

By

Vaccine

New Delhi, January 16

A 22-year-old security guard at AIIMS, New Delhi reported allergic reaction and is learnt to be in intensive care, moments after the government said there was no post-vaccine hospitalisation.

The 22-year-old guard developed headache, rash, respiratory distress, tachycardia after vaccination. He is in ICU and his condition is stable, hospital sources said.

Delhi has reported 52 adverse events following events of which one is serious and could involve the guard hospitalised today.

All beneficiaries vaccinated at AIIMS got indigenous COVAXIN.

Continue Reading
Advertisement

Most Popular